Novo Nordisk offloads preclinical cancer candidate from $1.1B Forma buyout
02 Mar 2023
Acquisition
When Novo Nordisk first approached Forma Therapeutics about a deal, the Danish drugmaker made clear that it was really only interested in Forma’s sickle cell drug etavopivat. Even though Forma ultimately convinced Novo to buy the whole company — complete with a slate of oncology programs — for $1.1 billion, Novo isn’t keeping all of them around.
Lausanne, Switzerland-based Debiopharm has bought from Novo global rights to FT-3171, a small molecule USP1 inhibitorUSP1 inhibitor program previously developed by Forma, it announced in a press release. No financials were provided.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 161,600+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.